Astrazeneca PLC (NYSE: AZN)
41 Days left to seek lead plaintiff status.
AstraZeneca and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (1) the Company engaged in insurance fraud in China; (2) as a result, the Company faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, the Company understated its legal risks; (4) the foregoing, once revealed, could materially harm the Company’s business activities in China; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.